Skip to Main Content

Liver Center News

Search for Affordable Treatment Option for Liver Disease

Until very recently, no treatment options were available for metabolic-associated steatolic liver disease (MASLD) (previously called non-alcoholic fatty liver disease). The Food and Drug Administration recently approved resmetirom, the first therapy for the more severe form of MASLD, but there remains a need for a generic, affordable treatment option for patients. Bubu Banini, MD, PhD, was recently awarded a $3.05 million R01 grant by the National Institutes of Health (NIH) for a five-year research project to investigate the feasibility of oral digoxin as a treatment option for these patients.

Read more
Get RSS Feed